The Federal Antimonopoly Service (FAS) of Russia has agreed on the price of the anti-tuberculosis drug Deltiba, which was announced by the manufacturer, R-Pharm. It will be 19 times lower than in the reference countries. This is reported in the official Telegram channel of the Service.
“The decrease became possible due to the expansion of the list of Vital and Essential Drugs (VED). The drug’s INN is delamanide, which has been included in the VED list since 2022,” the report says.
According to the data from the Service’s decisions database, one pack of Deltiba will cost 6312.68 rubles.
Deltiba, a drug developed for the treatment of resistant tuberculosis by the Japanese Otsuka Pharmaceutical Co., Ltd., is now produced by the R-Pharm group of companies. As it became known earlier, the drug has passed the procedure of entry into civil circulation, including additional testing with the involvement of an independent laboratory of Roszdravnadzor.
The FAS also canceled the previously agreed prices for Clopidogrel-Teva and agreed on the price of Cabatax, an antitumor drug.
